Technological advances in the design and delivery of mRNA have catalysed the rapid development of mRNA COVID-19 vaccines by ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Research shows respiratory viruses like flu and COVID can significantly increase the risk of heart attacks and strokes, ...

Discover how mRNA vaccines could revolutionize medicine by targeting 9 major diseases. Learn about breakthrough treatments ...

The recent death of a British woman from rabies is a sobering reminder of the risks posed by the fatal disease ...

Co-infection involves the simultaneous infection of a host by two or more different pathogens, a common occurrence that ...

A single dose of the antiviral baloxavir marboxil (Xofluza) led to a lower incidence of influenza virus transmission to household contacts compared with placebo, a phase IIIb randomized trial showed.

Common viral respiratory infections such as COVID-19, respiratory syncytial virus (RSV) and influenza are linked to an ...

The 2025 Warren Alpert Foundation Prize has been awarded to three scientists whose discoveries culminated in the development ...

Rabies is a usually fatal infection of the brain and nerves that can be caught if a person is bitten, scratched or licked by ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.